Wall Street Zen Upgrades Avalyn Pharma (NASDAQ:AVLN) to Hold

Avalyn Pharma (NASDAQ:AVLN) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.

AVLN has been the topic of several other reports. Raymond James Financial began coverage on Avalyn Pharma in a research report on Friday, October 2nd. They issued an “outperform” rating and a $60.00 price objective on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Avalyn Pharma in a research report on Wednesday. Finally, Morgan Stanley boosted their target price on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Avalyn Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

Avalyn Pharma Stock Down 1.0%

AVLN stock opened at $30.28 on Friday. Avalyn Pharma has a 1 year low of $22.24 and a 1 year high of $40.17. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The company has a 50 day moving average of $28.66.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.03). On average, research analysts expect that Avalyn Pharma will post -3.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Avalyn Pharma news, insider Fmr Llc sold 175,000 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $29.07, for a total transaction of $5,087,250.00. Following the transaction, the insider owned 2,109,535 shares of the company’s stock, valued at $61,324,182.45. This represents a 7.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Hedge Funds Weigh In On Avalyn Pharma

Institutional investors have recently added to or reduced their stakes in the business. State Street Corp boosted its stake in Avalyn Pharma by 73.7% in the 3rd quarter. State Street Corp now owns 554,004 shares of the company’s stock worth $15,784,000 after buying an additional 235,009 shares during the last quarter. Profund Advisors LLC purchased a new stake in Avalyn Pharma in the 3rd quarter valued at about $668,000. China Universal Asset Management Co. Ltd. purchased a new stake in Avalyn Pharma in the 3rd quarter valued at about $29,000. Manchester Capital Management LLC acquired a new position in shares of Avalyn Pharma during the 3rd quarter valued at about $36,000. Finally, Braidwell LP acquired a new position in shares of Avalyn Pharma during the 2nd quarter valued at about $26,382,000.

Avalyn Pharma Company Profile

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.